In breast cancer dose-expansion cohorts, 33% of patients with HER2-positive breast cancer achieved objective partial responses; additionally, 28% of patients with HER2-low, hormone receptor-positive breast cancer and 40% with HER2-low, hormone receptor-negative breast cancer also showed objective partial response. The gene discussed is NR4A1; the disease is breast carcinoma.